Revolution Medicines (NASDAQ:RVMD) Insider Alan Sandler Sells 6,309 Shares of Company Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) insider Alan Sandler sold 6,309 shares of the business’s stock in a transaction that occurred on Tuesday, September 29th. The stock was sold at an average price of $202.14, for a total value of $1,275,301.26. Following the transaction, the insider directly owned 52,559 shares in the company, valued at $10,624,276.26. The trade was a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Revolution Medicines Stock Performance

Revolution Medicines stock traded up $0.63 during mid-day trading on Thursday, hitting $205.89. 1,710,457 shares of the company’s stock traded hands, compared to its average volume of 2,893,928. The firm has a 50 day simple moving average of $202.11 and a two-hundred day simple moving average of $165.61. Revolution Medicines, Inc. has a fifty-two week low of $45.60 and a fifty-two week high of $224.31. The stock has a market cap of $44.13 billion, a price-to-earnings ratio of -23.34 and a beta of 1.40. The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same quarter in the previous year, the business posted ($1.31) EPS. On average, research analysts expect that Revolution Medicines, Inc. will post -8.87 EPS for the current fiscal year.

Hedge Funds Weigh In On Revolution Medicines

Institutional investors and hedge funds have recently modified their holdings of the business. Burkett Financial Services LLC bought a new position in Revolution Medicines during the third quarter worth about $27,000. Contravisory Investment Management Inc. bought a new stake in Revolution Medicines in the 2nd quarter valued at about $32,000. Johnson Financial Group Inc. bought a new stake in Revolution Medicines in the 2nd quarter valued at about $37,000. Silvant Capital Management LLC acquired a new position in shares of Revolution Medicines during the 2nd quarter worth approximately $41,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new position in shares of Revolution Medicines during the 2nd quarter worth approximately $41,000. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Revolution Medicines in a report on Friday, July 17th. Stifel Nicolaus raised their price objective on shares of Revolution Medicines from $215.00 to $230.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. Evercore restated an “outperform” rating and set a $320.00 price objective on shares of Revolution Medicines in a report on Thursday, August 27th. TD Cowen raised Revolution Medicines to a “strong-buy” rating in a research report on Monday, August 24th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and issued a $248.00 target price on shares of Revolution Medicines in a research report on Thursday, August 27th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $234.33.

About Revolution Medicines

Revolution Medicines, Inc is a clinical-stage biotechnology company focused on developing targeted therapies for patients with cancer. The company’s research centers on the RAS signaling pathway, a key driver of tumor growth that is altered in many cancers, including those involving KRAS mutations.

Its pipeline includes RAS(ON) inhibitors designed to target active RAS proteins and address a range of RAS-driven tumors. Key development programs include daraxonrasib (RMC-6236), a broad-spectrum RAS inhibitor, and zoldonrasib (RMC-9805), an investigational inhibitor aimed at KRAS G12D-mutated cancers.